Pharmaceutical market is continuing to see global growth, whereas pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy. Companies are considering various strategies to overcome the current challenges, with deal making being foremost among these as a means of boosting revenues over a short period of time.
Agreements between companies for drug discovery, which allow them to share the risk of co-developing products, have become more common. Small companies that primarily carry out early-stage research, development and production activities are entering into agreements with key industry leaders to out-license the rights to their products, utilizing the strengths of the larger companies in terms of commercialization expertise, manufacturing, distribution and marketing capabilities and global presence.
Meanwhile, key players keen to secure novel and promising molecules are willing to co-operate with small players to in-license promising early-stage assets to expand their portfolios, reduce R&D risks and move ahead in the market. Also, therapies have historically been manufactured in a one-size-fits-all approach for chronic diseases, among other therapy areas. Recently, a more personalized approach is being chosen by pharmaceutical companies, which are increasing the development of targeted therapies even for rare diseases.
The report ""Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics"" analyzes the importance of deal making in the pharmaceutical and healthcare market. There were a total of 2,028 deals made in 2016, with an aggregate deal value of $189 billion. Deal activity has a very wide range of purposes, including helping pharma companies to enhance their research and regulatory approaches, and aiding portfolio expansion and diversification, geographic expansion, entry into niche markets, commercialization, and sales.
Specifically, this report provides the following -
- Covers key factors that encourage deal activity in the pharmaceutical industry, and the key strategies being implemented when companies strike deals. These strategies can be utilized for a variety of purposes, including solidifying market presence, averting revenue losses due to key product patent expiries, increasing R&D potential and output, and expanding a company’s operations, products and overall presence in various geographies.
- An overview of recent deal activity from 2010 to May 2017 is provided. It covers -
- Number of deals and aggregate deal values
- Trends in deals by geography and major therapy area
- Trends in products involved in deals, based on molecule type, stage of development and type of deal
- Discusses key companies involved in deal making over recent years (2012-2016), and their recent key deal activity is analyzed.
- Recently announced M&As, licensing deals and partnership deals that took place between 2016 and Q1 2017 are analyzed.
Companies mentioned in this report: Pfizer, Merck, Bayer, Allergan, Valeant.
- What deal making strategies have been used in recent years to boost R&D productivity and allow the successful commercialization of pharmaceutical products?
- In which geographical markets and disease areas has deal activity been focused since 2010?
- At which stage of development did deals most frequently occur, and attract the highest value?
- How have pharma companies been using deal making to strengthen their product portfolio and bottom line?
- What are the most significant Mergers and Acquisitions (M&As), licensing deals and partnership deals to have been announced since 2016?
- Who are the major players in pharmaceutical deal making, and what has been their recent and key deal activity?
Key Reasons to Purchase
- Gain a comprehensive understanding of the most recent healthcare deal trends.
- Understand the most significant M&As, licensing deals and partnerships to have occurred in recent years.
- Comprehensively analyze the trends of deal activity from 2010 to May 2017, with respect to aggregate deal value, geography, and the therapy area and stage of development of the products involved.
- Understand the deal-making strategies that have been historically implemented by companies, and identify the most suitable strategies for boosting R&D portfolio and bottom line performance.
- Identify the key deal terminations that have occurred in recent years, and understand their effect.
- Factors Promoting Deal Activity
- Key Strategies Implemented in Deals
- Geographical Expansion
- Portfolio Enhancement
- Market Consolidation
- Improving Research and Development
- Product Lifecycle management
- Entry into Rare disease Markets
2. Deal Types
- Mergers and Acquisitions (M&As)
- Key Announced Deals in M&As
- Terminated M&As
- Asset Swaps
- Key Asset Swaps
- Key Announced Deals
- Terminated Partnerships
- Key Announced Deals
- Terminated Licensing deals
- Overview of Pharmaceutical Deals from 2010 to 2016
- Pharmaceutical Deals by Value and Year
- Number of Deals by Region/Country
- Number of Deals by Prominent Therapy Area
- Number of Deals by Stage of Development
- Number of Deals by Molecule Type
- Number of deals and Value by Type of Deal
5. Key Players
6. Conclusions and Future Scope